Topped – Earlybirds Invest https://earlybirdsinvest.com Latest Crypto News Sat, 02 Aug 2025 03:28:26 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.7 https://i0.wp.com/earlybirdsinvest.com/wp-content/uploads/2024/12/cropped-New-Project-2024-12-17T235703.455.png?fit=32%2C32&ssl=1 Topped – Earlybirds Invest https://earlybirdsinvest.com 32 32 240146708 Why Eli Lilly Stock Topped the Market Today https://earlybirdsinvest.com/why-eli-lilly-stock-topped-the-market-today/ https://earlybirdsinvest.com/why-eli-lilly-stock-topped-the-market-today/#respond Sat, 02 Aug 2025 03:28:25 +0000 https://earlybirdsinvest.com/why-eli-lilly-stock-topped-the-market-today/ Zepbound could benefit handsomely if an apparently planned government program is implemented.

Although mighty American pharmaceutical company Eli Lilly (LLY 2.95%) has a dizzying number of commercialized products, it’s a recently approved medication that’s attracted outsized attention lately. This is its GLP-1 weight-loss drug, Zepbound. On Friday, thanks to news of a large Federal subsidy program apparently in the works, shares of the drug’s maker leaped more than 3% higher in value.

A half-decade experiment

That morning The Washington Post, citing official documents it had obtained from the Centers for Medicare and Medicaid Services (CMS), provided details of that program.

Two medical professionals in white lab coats looking at a computer display.

Image source: Getty Images.

The agency aims to launch a five-year pilot initiative under which Medicare Part D insurance providers and state Medicaid programs would be permitted to cover the costs of obesity drugs. This would help remove a major hurdle for some otherwise qualifying patients, as expenses for the regularly administered Zepbound can add up significantly.

The report comes a day after President Trump sent a series of letters to top U.S. healthcare company CEOs insisting that they lower the prices of important treatments. If implemented, this apparent experimental program would fit with the White House’s recent cost-saving push for the many Americans using medications.

Details wanted

It wasn’t much of a surprise that investors cautiously bid up Eli Lilly stock — and that of its GLP-1 drug making rival, Wegovy developer Novo Nordisk — following the article’s publication. Any such program would certainly be a boon for both products and their manufacturers, although much remains to be parsed when and if more details about the CMS’s program become available.

]]>
https://earlybirdsinvest.com/why-eli-lilly-stock-topped-the-market-today/feed/ 0 50992
Why AstraZeneca Stock Topped the Market on Tuesday https://earlybirdsinvest.com/why-astrazeneca-stock-topped-the-market-on-tuesday/ https://earlybirdsinvest.com/why-astrazeneca-stock-topped-the-market-on-tuesday/#respond Tue, 01 Jul 2025 22:02:27 +0000 https://earlybirdsinvest.com/why-astrazeneca-stock-topped-the-market-on-tuesday/

Trading in AstraZeneca‘s (AZN 2.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session. With that rise, it did better than the S&P 500 (^GSPC -0.11%), which closed the day marginally (0.1%) lower.

Bye-bye Britain?

That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to move the company’s stock market listing onto our shores (ADSes are certificates conferring ownership of a stock, not the stock itself).

Illuminated exit sign.

Image source: Getty Images.

Citing unidentified multiple sources, the newspaper wrote that Soriot might also be mulling a move of AstraZeneca’s headquarters from the U.K. to the U.S.

Currently, the global healthcare company is a component of the FTSE 100, considered by many to be the most important U.K. stock index.

According to The Times‘ reporting, the chief executive is “known to be deeply frustrated with the U.K.’s operating environment.” The newspaper added that he has publicly expressed concern about what he perceives to be a decline in European competitiveness against the U.S. and China. The pair happens to be the company’s two largest markets.

Neither Soriot nor AstraZeneca has yet officially commented on the article.

Land of opportunity

Since AstraZeneca has quite a presence in the U.S. healthcare market and does much of its business in the country, it makes abundant sense to shift the main stock market listing and even the headquarters here. It’s unclear (at least for now) how much this might affect the company’s fundamentals and operations, but as a concept, it’s a good idea.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.

]]>
https://earlybirdsinvest.com/why-astrazeneca-stock-topped-the-market-on-tuesday/feed/ 0 45235
Has Bitcoin Topped Out? This Key Metric Suggests Otherwise https://earlybirdsinvest.com/has-bitcoin-topped-out-this-key-metric-suggests-otherwise/ https://earlybirdsinvest.com/has-bitcoin-topped-out-this-key-metric-suggests-otherwise/#respond Wed, 18 Jun 2025 23:51:16 +0000 https://earlybirdsinvest.com/has-bitcoin-topped-out-this-key-metric-suggests-otherwise/

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

On-chain data shows the Bitcoin Market Value to Realized Value (MVRV) Ratio is currently still below historical market peaks.

Bitcoin MVRV Ratio May Not Be That Overheated Yet

In a new post on X, the institutional DeFi solutions provider Sentora (previously IntoTheBlock) has discussed about the latest trend in the MVRV Ratio of Bitcoin. The “MVRV Ratio” refers to a popular on-chain indicator that compares the BTC Market cap and Realized cap.

The Realized Cap is an on-chain capitalization model for the asset that calculates its total valuation by assuming the value of each individual token in circulation is equal to the price at which it was last moved on the network. This is different from the usual Market Cap, which just takes the current spot price as the value for all coins.

The previous transaction of any token is likely to represent the last time that it changed hands, so the price at its time could be considered as its current cost basis. Thus, the Realized Cap is essentially the sum of the acquisition values of all coins.

One way to interpret the model is as a measure of the amount of capital that investors as a whole initially put into the cryptocurrency. In contrast, the Market Cap represents the value that they are holding right now.

As the MVRV Ratio takes the ratio of the two models, its value basically tells us whether the investors are holding more than they put in. In other words, the indicator contains information about the profit-loss balance of the entire network.

Now, here is the chart shared by Sentora that shows a long-term view of the Bitcoin MVRV Ratio:

Bitcoin MVRV Ratio

The trend in the BTC MVRV Ratio over the past ten years | Source: Sentora on X

As is visible in the above graph, an extreme peak in the Bitcoin MVRV Ratio has historically coincided with tops in the asset’s price. The explanation behind the pattern lies in the fact that investors become more tempted to take their gains the larger that they grow.

At a high value of the MVRV Ratio, the Market Cap significantly exceeds the Realized Cap, so the average investor can be assumed to be holding onto a notable profit. This often leads to holders participating in mass selloffs to realize their gains, but the bull run keeps going as long as enough demand continues to flow in to absorb the selling pressure.

From the chart, it’s apparent that this balance seems to have been reaching a turning point earlier with each cycle, showcasing that as Bitcoin matures as an asset, its returns are becoming smaller. At present, the MVRV Ratio is sitting at a value of 2.25, which suggests the Market Cap is more than double the Realized Cap. However, even after taking into account for shrinking gains, this value is notably lower than previous cyclical tops.

“This indicates the market still isn’t as overheated as it was during earlier peaks,” notes the analytics firm. It now remains to be seen how the rest of the cycle will play out, and whether BTC will make use of this potential room or not.

BTC Price

Bitcoin has erased its recent recovery as its price has come back down to the $104,200 mark.

Bitcoin Price Chart

Looks like the price of the coin has plunged during the last couple of days | Source: BTCUSDT on TradingView

Featured image from Dall-E, IntoTheBlock.com, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

]]>
https://earlybirdsinvest.com/has-bitcoin-topped-out-this-key-metric-suggests-otherwise/feed/ 0 42814